These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31599067)

  • 1. Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis.
    Kannt A; Papada E; Kammermeier C; D'Auria G; Jiménez-Hernández N; Stephan M; Schwahn U; Madsen AN; Østergaard MV; Dedoussis G; Francino MP;
    Mol Nutr Food Res; 2019 Dec; 63(24):e1900927. PubMed ID: 31599067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
    Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
    Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    Flensted-Jensen M; Oró D; Rørbeck EA; Zhang C; Madsen MR; Madsen AN; Norlin J; Feigh M; Larsen S; Hansen HH
    BMC Gastroenterol; 2024 Feb; 24(1):59. PubMed ID: 38308212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
    Carter JK; Bhattacharya D; Borgerding JN; Fiel MI; Faith JJ; Friedman SL
    PLoS One; 2021; 16(1):e0244763. PubMed ID: 33395434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artemisia argyi ethanol extract ameliorates nonalcoholic steatohepatitis-induced liver fibrosis by modulating gut microbiota and hepatic signaling.
    Erdenebileg S; Kim M; Nam Y; Cha KH; Le TT; Jung SH; Nho CW
    J Ethnopharmacol; 2024 Oct; 333():118415. PubMed ID: 38848971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fecal mycobiome in non-alcoholic fatty liver disease.
    Demir M; Lang S; Hartmann P; Duan Y; Martin A; Miyamoto Y; Bondareva M; Zhang X; Wang Y; Kasper P; Bang C; Roderburg C; Tacke F; Steffen HM; Goeser T; Kruglov A; Eckmann L; Stärkel P; Fouts DE; Schnabl B
    J Hepatol; 2022 Apr; 76(4):788-799. PubMed ID: 34896404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice.
    Wyss J; Raselli T; Wyss A; Telzerow A; Rogler G; Krupka N; Yilmaz B; Schmidt TSB; Misselwitz B
    BMC Microbiol; 2024 Feb; 24(1):69. PubMed ID: 38418983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
    Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
    Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium Reduces Liver Injury in Mice on a High-Fat Diet: Alterations in Microbial and Bile Acid Profiles.
    Nadeem Aslam M; Bassis CM; Zhang L; Zaidi S; Varani J; Bergin IL
    PLoS One; 2016; 11(11):e0166178. PubMed ID: 27851786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
    Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
    Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
    Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soyasaponin A
    Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
    Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.